| |
|
| Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes | 4.73 MB | Download | These data demonstrate than an opioid antagonist, Naloxone, may prevent both IFN- and IL-2-mediated increases in human NK function. | 152 |
|
| LDN Circular | 78.19 KB | Download | RX Circular: Uses, warnings, cautions and side effects on the packaging | 214 |
|
| Fibromyalgia Treatment | 34.50 KB | Download | Stanford's Clinical Trial of Naltrexone Recruiting Patients | 245 |
|
| Increased Brain Size and Cellular Content in Infant Rats Treated with an Opiate Antagonist (1983) | 467.48 KB | Download | Increased Brain Size and Cellular Content in Infant Rats Treated with an Opiate Antagonist (1983) | 134 |
|
| More Than A Magic Bullet: LDN | 62.94 KB | Download | by Elaine Moore. "Low dose naltrexone (LDN) is a hot topic among patients with multiple sclerosis (MS), cancer, neurological conditions, HIV infection, herpes, autism, and autoimmune diseases..." | 221 |
|
| The LDN Protocol Controversy | 88.12 KB | Download | The erroneous supposition that LDN must be taken at night only. | 252 |
|
| LDN Dosing | 31.41 KB | Download | In the protocol LDN, naltrexone is prescribed off-label in doses ranging from 1.5-10 mg daily, depending on body weight and symptoms. A dose of 4.5 mg is generally recommended for patients weighing approximately 150 lbs. | 228 |
|
| Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease | 128.12 KB | Download | LDN therapy appears effective and safe in subjects with active Crohn’s disease. | 180 |
|
| Endogenous opioids, opioids receptors, and cancer (1990) | 599.30 KB | Download | Endogenous opioids, opioids receptors, and cancer (1990) | 177 |
|
| AHSTA Newsletter July 2008 | 576.41 KB | Download | LDN story, LDN dosing, and a quick look at survey responses. | 398 |
|
| AHSTA Newsletter September 2008 | 251.69 KB | Download | Includes personal story on using LDN to stop the progression of multiple autoimmune diseases. | 145 |
|
| AHSTA Chat Transcript, Jan 2009 | 149.40 KB | Download | Elaine Moore introduces her new book "The Promise of Low Dose Naltrexone Therapy" in this AHSTA chat event. | 149 |
|
| AHSTA Chat Transcript, May 2008 | 116.78 KB | Download | AHSTA sponsors LDN Q&A chat event with Elaine Moore | 179 |
|
| Compounding Pharmacies | 312.96 KB | Download | List of compounding pharmacies plus brochure | 373 |
|
| Defects in the OGFr in Human Squamous Cell Carcinoma of Head and Neck | 545.48 KB | Download | This study compared protein and gene expression of OGFr in surgical specimens of human squamous cell carcinoma of the head and neck with normal epithelium. | 140 |
|
| Benefits of Low Dose Naltrexone | 29.13 KB | Download | Immunomodulatory and Biochemical Effects of LDN | 296 |
|
| Biology of the opioid growth factor receptor (OGFr) | 3.08 MB | Download | The native opioid growth factor, Metenkephalin, is a tonic inhibitory peptide that plays a role in cell proliferation and tissue organization during development, cancer, cellular renewal and wound healing. | 167 |